Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -115.57% is 23% above its 5-year average of -149.86%, around the middle of its 5-year range (-286.57%–-33.43%).
12.05% above its 12-month average of -131.41%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-06-30): -32.43%.
RETURN ON ASSETS (ROA)
-115.57%
RETURN ON ASSETS (ROA) AVG TTM
-131.41%
RETURN ON ASSETS (ROA) AVG 3Y
-121.81%
RETURN ON ASSETS (ROA) AVG 5Y
-149.86%
RETURN ON ASSETS (ROA) AVG 10Y
-976.69%
RETURN ON ASSETS (ROA) AVG 15Y
-1152.20%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+12.05%
CURRENT VS 3Y AVG
+5.13%
CURRENT VS 5Y AVG
+22.88%
CURRENT VS 10Y AVG
+88.17%
CURRENT VS 15Y AVG
+89.97%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.75%
median of 809 covered companies
CURRENT VS SECTOR MEDIAN
-264.00%
vs the sector median at left
NeuroOne Medical Technologies Corporation
Market Cap
$9.70M
Return on Assets (ROA)
-115.57%
TTM Avg
-131.41%
3Y Avg
-121.81%
5Y Avg
-149.86%
Market Cap
$9.68M
Return on Assets (ROA)
-73.89%
TTM Avg
-61.17%
3Y Avg
-50.83%
5Y Avg
-128.36%
Market Cap
$9.88M
Return on Assets (ROA)
-108.85%
TTM Avg
-94.23%
3Y Avg
-71.21%
5Y Avg
-107.74%
Market Cap
$10.10M
Return on Assets (ROA)
-204.84%
TTM Avg
-224.84%
3Y Avg
-332.29%
5Y Avg
-789.37%
Market Cap
$9.31M
Return on Assets (ROA)
-157.56%
TTM Avg
-309.44%
3Y Avg
-441.71%
5Y Avg
-440.28%
Market Cap
$9.13M
Return on Assets (ROA)
-269.20%
TTM Avg
-150.53%
3Y Avg
-111.73%
5Y Avg
-102.54%
Market Cap
$10.33M
Return on Assets (ROA)
-149.72%
TTM Avg
-86.94%
3Y Avg
-66.39%
5Y Avg
-60.64%
Market Cap
$10.34M
Return on Assets (ROA)
N/A
TTM Avg
-21.71%
3Y Avg
-73.35%
5Y Avg
-116.85%
Market Cap
$9.04M
Return on Assets (ROA)
-6.36%
TTM Avg
-31.97%
3Y Avg
-31.64%
5Y Avg
-61.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroOne Medical Technologies Corporation (NMTC) | $9.70M | -115.57% | -131.41% | -121.81% | -149.86% |
| Ainos, Inc. (AIMD)vs › | $9.68M | -73.89% | -61.17% | -50.83% | -128.36% |
| MetaVia Inc. (MTVA)vs › | $9.88M | -108.85% | -94.23% | -71.21% | -107.74% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.10M | -204.84% | -224.84% | -332.29% | -789.37% |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.31M | -157.56% | -309.44% | -441.71% | -440.28% |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.13M | -269.20% | -150.53% | -111.73% | -102.54% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.33M | -149.72% | -86.94% | -66.39% | -60.64% |
| Polyrizon Ltd. (PLRZ)vs › | $10.34M | N/A | -21.71% | -73.35% | -116.85% |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.04M | -6.36% | -31.97% | -31.64% | -61.82% |
| Satellos Bioscience Inc. (MSLE)vs › | $10.44M | -52.23% | -58.24% | -82.00% | -104.09% |
ROA
-115.6%
ROE
-189.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | -33.43% |
| 2024-09-30 | -229.39% |
| 2023-09-30 | -146.46% |
| 2022-09-30 | -77.98% |
| 2021-09-30 | -125.32% |
| 2020-09-30 | -286.57% |
| 2019-09-30 | -1273.18% |
| 2018-09-30 | -3121.25% |
| 2017-12-31 | -2023.49% |
| 2016-12-31 | -6.31% |
| 2015-12-31 | -3420.18% |
| 2014-12-31 | -17680.00% |
| 2013-12-31 | -5025.33% |
| 2012-12-31 | -1248.66% |
| 2011-12-31 | -199.29% |
| 2010-12-31 | -66.21% |
